Ning Sheng, PhD, is an Associate Research Fellow at the Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College (CAMS & PUMC). With expertise in drug target discovery, novel drug development, and clinical biomarker exploration, Sheng specializes in utilizing cutting-edge proteomics and metabolomics technologies. Sheng holds a Doctor of Science degree in Pharmaceutical Analysis from CAMS & PUMC. Throughout their career, Sheng has contributed significantly to research in mitochondrial protection, neuroprotection, chronic cerebral ischemia treatment, and preclinical drug development. They are proficient in operating various mass spectrometers and utilizing proteomics software.
Author Metrics:
Scopus Profile
ORCID Profile
Ning Sheng has authored and co-authored several notable articles in the last five years, focusing on various aspects of pharmaceutical analysis, drug development, and treatment of neurological diseases. Sheng’s publications have appeared in reputable journals, contributing to the advancement of knowledge in proteomics, metabolomics, and pharmacokinetics. They have also received funding from prestigious organizations, indicating recognition for their research contributions.
- 367 citations by 353 documents
- 31 documents authored
- 10 h-index
Education:
Ning Sheng obtained their Doctor of Science degree in Pharmaceutical Analysis from the Chinese Academy of Medical Science and Peking Union Medical College (CAMS & PUMC) in July 2018. Their educational background equipped them with the necessary knowledge and skills to excel in their research endeavors, particularly in the fields of proteomics and metabolomics.
Research Focus:
Sheng’s research primarily focuses on drug target discovery, novel drug development, and clinical biomarker exploration. They utilize advanced proteomics and metabolomics technologies to investigate mitochondrial protection, neuroprotection, and the treatment of chronic cerebral ischemia. Sheng’s work aims to contribute to the development of effective therapeutic interventions for neurological diseases and other medical conditions.
Professional Journey:
Sheng began their professional journey as an Assistant Research Fellow at the Institute of Materia Medica, CAMS & PUMC, in August 2018. They were later promoted to Associate Research Fellow in July 2021. Throughout their career, Sheng has demonstrated expertise in proteomics, metabolomics, and preclinical drug development, contributing to several research projects and publications.
Honors & Awards:
Ning Sheng has received recognition for their research contributions through various honors and awards. Their notable achievements include being the project leader for the National Natural Science Foundation of China (No. 82204341) and participating in other significant research projects funded by prestigious organizations.
Publications Noted & Contributions:
Sheng’s publications have made significant contributions to the field of pharmaceutical analysis and drug development. Their research on mitochondrial proteomics, metabolomics, and preclinical drug development has been published in reputable journals such as Advances in Science and Pharmacological Research. Sheng’s work has provided valuable insights into the mechanisms of action of potential therapeutic agents and the treatment of neurological diseases.
Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca2+/CaMKII pathway
Journal: Journal of Pharmaceutical Analysis, 2024-03
DOI: 10.1016/j.jpha.2023.09.016
Contributors: Congyu Ma; Ning Sheng; Jun Wu; Lulu Wang; Jiandong Jiang; Haibo Yu; Jinlan Zhang
Scutellarin Rescued Mitochondrial Damage through Ameliorating Mitochondrial Glucose Oxidation via the Pdk‐Pdc Axis
Journal: Advanced Science, 2023-11
DOI: 10.1002/advs.202303584
Contributors: Ning Sheng; Zhihui Zhang; Hao Zheng; Congyu Ma; Menglin Li; Zhe Wang; Lulu Wang; Jiandong Jiang; Jinlan Zhang
A novel derivatization strategy for profiling phosphate ester/anhydride metabolic network and application on glioma rats using HILIC-MS/MS
Journal: Talanta, 2021
DOI: 10.1016/j.talanta.2021.122238
Contributors: Sheng, N.; Zhao, H.; Chen, X.; Wang, D.; Li, M.; Wang, Z.; Zhang, J.; Jiang, J.
Advances in Mass Spectrometric-Based Technologies and Strategies for the Analysis of Traditional Chinese Medicine, 中药成分质谱分析新技术和新策略进展
Journal: Journal of Chinese Mass Spectrometry Society, 2021
DOI: 10.7538/zpxb.2021.0107
Contributors: Ma, C.-Y.; Sheng, N.; Li, Y.-Y.; Wang, Z.; Zhang, J.-L.
An efficient approach to probe the bioactive transdermal components of traditional Chinese herbal patches by UHPLC-MS: Gutong patch as a case
Journal: Phytomedicine, 2021
DOI: 10.1016/j.phymed.2021.153776
Contributors: Ma, C.; Sheng, N.; Shi, G.; Zhang, J.; Zhang, T.
These publications demonstrate Ning Sheng’s involvement in various research projects spanning from the analysis of traditional Chinese medicine to the investigation of novel therapeutic approaches for cognitive impairment and mitochondrial damage. Sheng’s contributions encompass diverse topics in pharmaceutical analysis, metabolomics, and drug development, indicating a broad expertise in their field.
Research Timeline:
Sheng’s research timeline spans from their doctoral studies to their current position as an Associate Research Fellow. Over the years, they have been involved in various research projects focusing on drug target discovery, novel drug development, and clinical biomarker exploration. Their research timeline highlights their continuous dedication to advancing scientific knowledge and contributing to the field of pharmaceutical analysis.
Collaborations and Projects:
Throughout their career, Sheng has collaborated with other researchers and participated in various research projects funded by national and international organizations. Their collaborations have led to significant contributions in proteomics, metabolomics, and preclinical drug development. Sheng’s involvement in collaborative projects underscores their commitment to interdisciplinary research and advancing scientific understanding in their field.
